Panitumimab in combination with radiotherapy in patients with locally advanced KRAS wildtype rectal cancer (clinical stages II and III)

The primary objective of the study is to estimate the efficacy of panitumumab concurrent to radiotherapy in patients with wild-type KRAS. The rate of pathological complete remissions will be compared to expectations derived from historical data.